What actually happened today is small but worth naming plainly. MindMed's stock (ticker MMED) rose almost 10% while nobody announced anything to explain it. COMPASS, the company furthest along in testing psilocybin — the active ingredient in magic mushrooms — for depression, slipped about 2%. Its shares sit near $13. There was no new government ruling, no new drug application, no court decision. At the same time, a couple of safety stories have been circulating in the mainstream press — including a celebrity, Scott Wolf, linked to a psychosis episode, and warnings about poisonous wild mushrooms.
Beneath the surface, a real pattern is forming. When there is no fresh good news, two things fill the silence: stock swings that mean nothing, and safety scares that mean something. The MindMed jump is most likely just traders chasing momentum — buying because others are buying. If the company stays silent for the next three weeks, that pump will probably fade. Meanwhile, editors have caught the scent of the safety angle, and more psychosis-and-mushroom stories are likely in the coming weeks. None of this is the enemy of progress. It is the ordinary weather a young field passes through before its real proof arrives. The deeper truth is that the important work — the careful, slow testing that has to hold up under strict review — is still maturing in the background, out of the headlines.
For the real people waiting inside this story, quiet days are hard. The veteran hoping ibogaine or ketamine might finally quiet the addiction or the nightmares. The person with depression that no pill has touched, watching for the day psilocybin becomes something a doctor can legally offer. To them, a flat news day can feel like being forgotten. But there is something honest and even kind in this pause. The best outcome for them is not a rushed approval that later collapses under scrutiny — it is a treatment that arrives proven, trusted, and here to stay. Slow is not the same as stalled. The kitchen is still lit. The meal is still being made. And a field that survives its scary headlines without losing its footing is a field growing roots strong enough to hold weight.
The most positive path genuinely open from here is simple: let the loud noise be loud, and let the quiet work stay quiet and careful. A safety scare handled with honesty builds more lasting trust than any hype ever could. A stock that jumps on nothing and settles back on nothing teaches investors to wait for real evidence — and that patience is exactly what serious medicine needs. The transmission today is that nothing breaking is not nothing happening.
The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first.
What is forming beneath the surface is always closer than it appears.
70%
No psilocybin antidepressant drug application reaches FDA before early 2027
No company will formally submit a psilocybin-based depression drug for approval to the FDA (the US drug regulator) before the end of March 2027. COMPASS Pathways, the leading company in this space, still needs to finish collecting long-term data on how well its treatment holds up over time before it can even prepare that submission. This means no psilocybin depression pill or therapy is getting officially reviewed anytime soon.
→ Psilocybin is not getting FDA approval for depression anytime soon — the key long-term data isn't ready yet. Confidence: 70%
Resolves: 2027-03-31 · USA
CLINICAL
the precise call ▾
No psilocybin depression NDA is accepted for FDA filing before Q1 2027; COMPASS remains pre-submission.. CMPS shows no imminent catalyst. Rigorous review requires durability data still maturing; COMPASS Phase 3 durability readout not yet reported. Filing readiness lags the hype. || RESOLUTION RULE: YES if, as of 2027-03-31, no company has publicly announced FDA acceptance of an NDA for a psilocybin the
62%
A new study or trial will launch testing ketamine for opioid addiction
Within ten weeks — by November 15, 2026 — at least one new clinical trial testing ketamine as a treatment for opioid addiction will be officially registered on the US government's trial database (ClinicalTrials.gov), or a research team will publish a detailed plan for such a study. Ketamine is already used in hospitals and clinics, so the infrastructure to run these studies exists. The opioid crisis also means there's real government money chasing new treatments.
→ Ketamine's potential to treat opioid addiction is gaining real scientific momentum, and new trials should launch within weeks. Confidence: 62%
Resolves: 2026-11-15 · Global
CLINICAL
the precise call ▾
At least one new ketamine-for-OUD clinical trial registration or published protocol appears within 10 weeks, building on today's OUD signal.. The Ketamine-for-OUD signal reflects genuine research momentum. Opioid crisis funding plus existing ketamine infrastructure make OUD the next expansion frontier. || RESOLUTION RULE: YES if a new interventional trial studying ketamine for opioid use disorder is first-registered on clinicaltrials.gov
66%
Mainstream media will run more scary psychedelic safety stories by mid-October
Within six weeks of September 1, 2026, at least two major news outlets — think Reuters, the New York Times, the BBC, or CNN — will publish prominent stories about people experiencing psychosis or other serious harms from psychedelics. Editors have already noticed readers engage with these fear-driven stories, so more are coming. When these stories run, they tend to spook everyday investors in psychedelic companies.
→ More scary psychedelic headlines are coming soon, and they'll likely rattle retail investors even if the underlying science is more nuanced. Confidence: 66%
Resolves: 2026-10-13 · Global
CULTURE
the precise call ▾
At least two more mainstream psychedelic-psychosis/adverse-event stories run within 6 weeks, pressuring retail sentiment on CMPS/ATAI.. The Scott Wolf psychosis story plus the toxic-mushroom warning show editors chasing the safety angle. Celebrity psychosis narratives compound. The hype-to-fear pivot is underway. || RESOLUTION RULE: YES if at least two distinct articles from mainstream outlets (Reuters, AP, NYT, WaPo, Guardian, BBC,
63%
No psychedelic-focused bill gets a formal House vote in committee before year-end
A 'committee markup' is the formal step where a congressional committee debates, amends, and votes on a bill before it can advance toward becoming law. No standalone bill specifically about psychedelics will reach that step in the US House of Representatives before December 31, 2026. Any real psychedelic policy progress this year will happen quietly through state-level programs or tucked inside bigger spending bills.
→ Congress won't formally advance any psychedelic bill this year — state programs and budget riders are the only game in town. Confidence: 63%
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
No standalone psychedelic bill gets a House committee markup before year-end; movement happens only through state pilots or appropriations.. The legislative calendar today confirms priorities lie elsewhere. Members won't get ahead of districts without cover from state successes; standalone psychedelic bills lack committee traction. || RESOLUTION RULE: YES if no standalone psychedelic-focused bill receives a full committee markup in the U
62%
COMPASS Pathways stock stays stuck below $16 through October with no buyout offer
COMPASS Pathways stock (trading on the Nasdaq stock exchange under the symbol CMPS) will close every single trading day at or below $16 between now and October 31, 2026, and no bigger company will swoop in with a buyout offer during that stretch. Without a clear date for when key trial results will be announced, big institutional investors — the pension funds and asset managers that move markets — have little reason to pile in.
→ COMPASS stock is likely to drift sideways below $16 all the way through October, with no rescue buyout in sight. Confidence: 62%
Resolves: 2026-10-31 · USA
MARKET
the precise call ▾
CMPS stays below $16 through October absent a Phase 3 durability readout; no M&A bid emerges this quarter.. At $13.23 and down today, COMPASS lacks a near-term catalyst. Institutions want de-risked filing-stage assets. Until a readout date is set, it drifts. || RESOLUTION RULE: YES if CMPS (NASDAQ:CMPS) closes at or below $16.00 on every trading day from 2026-09-01 through 2026-10-31 AND no acquisition/te